Announcements
- Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
- Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
- Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
- Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
- Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
- Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
- Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
- Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
- Lantheus Announces CEO Succession Plan
- Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
More ▼
Key statistics
On Friday, Lantheus Holdings Inc (0L8:DUS) closed at 61.38, -14.18% below its 52-week high of 71.52, set on Dec 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 61.08 |
---|---|
High | 61.50 |
Low | 61.04 |
Bid | 60.70 |
Offer | 61.90 |
Previous close | 59.92 |
Average volume | 29.60 |
---|---|
Shares outstanding | 68.55m |
Free float | 66.79m |
P/E (TTM) | 14.12 |
Market cap | 4.49bn USD |
EPS (TTM) | 4.64 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 18:30 BST.
More ▼